Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Acute myeloid leukemia with t(8;21)(q22;q22.1)/RUNX1-RUNX1T1 and KIT Exon 8 mutation is associated with characteristic mastocytosis and dismal outcomes.
Exp Mol Pathol
June 2019
Departments of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America. Electronic address:
KIT mutations are observed in about 20-40% of acute myeloid leukemia with t(8;21)(q22;q22.1)/RUNX1-RUNX1T1 [abbreviated AML t(8;21) here] with mutations involving exon 17 being the most common. Despite high frequencies of KIT mutations in both AML t(8;21) and systemic mastocytosis (SM), AML t(8;21) associated with SM is uncommon, and restricted to KIT exon 17 mutated cases.
View Article and Find Full Text PDFRole of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion.
Ann Hematol
July 2018
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
AML is stratified into risk-categories based on cytogenetic and molecular features that prognosticate survival and facilitate treatment algorithms, though there is still significant heterogeneity within risk groupings with regard to risk of relapse and prognosis. The ambiguity regarding prognosis is due in large part to the relatively outdated criteria used to determine response to therapy. Whereas risk assessment has evolved to adopt cytogenetic and molecular profiling, response criteria are still largely determined by bone marrow morphologic assessment and peripheral cell count recovery.
View Article and Find Full Text PDFMonitoring of fusion gene transcripts to predict relapse in pediatric acute myeloid leukemia.
Pediatr Int
January 2018
Clinical Research Center, National Hospital Organization Nagoya Medical Center, Aichi, Japan.
Background: In acute myeloid leukemia (AML), accurate detection of minimal residual disease (MRD) enables better risk-stratified therapy. There are few studies, however, on the monitoring of multiple fusion transcripts and evaluation of their accuracy as indicators of MRD at multiple time points.
Methods: We retrospectively examined RNA obtained from 82 pediatric AML patients enrolled in the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-05 study.
[Chemotherapy for a child with relapsed acute myeloid leukemia complicated with persistent hepatitis C virus infection].
Rinsho Ketsueki
November 2017
Department of Pediatrics, St. Luke's International Hospital.
An 8-year-old Mongolian female was diagnosed with acute myeloid leukemia (AML) and treated at a hospital in Mongolia according to the BFM-AML2004 SR protocol. Although complete remission (CR) was achieved, chemotherapy was interrupted because of shortage of drugs. The patient moved to Japan 7 months after diagnosis.
View Article and Find Full Text PDFAction mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies.
Cancer Sci
November 2016
Department of Hematology, Tokyo Women's Medical University, Tokyo, Japan.
Histone deacetylases (HDACs) critically regulate gene expression by determining the acetylation status of histones. Studies have increasingly focused on the activities of HDACs, especially involving non-histone proteins, and their various biological effects. Aberrant HDAC expression observed in several kinds of human tumors makes HDACs potential targets for cancer treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!